Browsing by Author "Seçmeler, Şaban"

Now showing 1 - 4 of 4

Adrenocortical Carcinoma: Single Center Experience
(2020) Seçmeler, Şaban; Can, Orcun; Yasar, Nurgul; Geredeli, Caglayan; Demir, Cumhur; Sakin, Abdullah; Cihan, Sener
Objective: The prevalence of adrenocortical carcinoma (ACC) is approximately 0.02% of all cancers, and the annual incidence is approximately 1-2 per million population. ACC is more aggressive, and the prognosis of ACC is poorer in adults than that in pediatric patients. We aimed to investigate the clinicopathological characteristics and factors affecting overall survival (OS) in patients with ACC who were followed-up and treated in our hospital.Methods: The patients, who were treated and followed up in the oncology clinic between 2006 and 2018, were included in the study. The patients who were diagnosed with ACC in the pathologic evaluation were included.Results: A total of 10 patients, five men (50%) and five women (50%), were included in the study. The mean age was 42.4 years (range=18-67). Six patients (60%) were stage 3, and four patients (40%) were stage 4. Eight patients (80%) underwent surgery. The release of glucocorticoid and/or androgen was detected in six patients (60%). Recurrence developed in six patients (100%), and seven patients (70%) died during the follow-up. The median OS was 13 months in patients with stage 3 disease, and the median OS was eight months in patients with stage IV disease (Log-rank p=0.177). The eastern cooperative oncology group performance status (ECOG PS) and performing of surgery were detected as the most significant factors affecting OS (Log-rank p=0.01, Log-rank p=0.02).Conclusion: The significant factors for OS were found to be surgery and ECOG PS in our study.
The Clinical Importance of Fibroblast Growth Factor 23 on Advanced Non-Small Cell Lung Cancer Patients Without Druggable Alterations in Genes as Egfr or Alk or Ros1 Fibroblast Growth Factor 23 and Non-Small Cell Lung Cancer
(2020) Cihan, Şener; Çekin, Ruhper; Seçmeler, Şaban; Atcı, Muhammed Mustafa; Ocak, Birol; Sakin, Abdullah; Arıcı, Serdar
Objectives: We aimed to investigate the relation between serum fibroblast growth factor (FGF) 23 levels and clinicopathologic features of stage 3B and 4 non-small cell lung cancer (NSCLC) patients without druggable alterations ingenes as epidermal growth factor receptor (EGFR) or rearrangements of the anaplastic lymphoma kinase (ALK) or c-ROSoncogene 1 (ROS1), by comparing healthy control group.Methods: This was a prospective, single-center study. Newly diagnosed stage 3B and 4 NSCLC patients without druggable alterations in genes as EGFR, ALK or ROS1 and healthy control in similar age, without any chronic disease andvitamin D deficiency were enrolled in the study. Fibroblast growth factor 23 levels were compared between groups.Results: Forty men newly diagnosed stage 3B and 4 patients and 24 healthy men were enrolled. The median age ofpatients and controls were 54.7 and 53.1 years. The number of patients were 22 (55.0%) and 18 (45.0%) in stage 3B andstage 4 groups respectively. The mean FGF 23 level was calculated as 87.7±58.0 pg/ml in patients group and 63.1±11.4pg/ml in control group (p=0.045). Fibroblast growth factor 23 levels were 85.5±42.5 pg/ml and 89.6±69.1 in metastaticand non-metastatic patients respectively (p=0.532). The median FGF 23 levels were 91.1±58.4 pg/ml and 92.5±60.8 pg/ml in squamous cell carcinoma and adenocarcinoma groups respectively (p=0.926).Conclusion: Our study suggests that high FGF-FGFR interaction may be causative for stage 3B and 4 NSCLC withoutdruggable alterations in genes as EGFR, ALK or ROS1 and is important in terms of suggesting the FGF pathway as a newtreatment target in NSCLC patients.
The Effects of Fulvestrant Treatment on Hormone Receptor-Positive Metastatic Breast Cancer
(2020) Geredeli, Çağlayan; Cihan, Sener; Arıcı, Serdar; Seçmeler, Şaban; Yasar, Nurgul; Sakin, Abdullah; Can, Orcun
Objectives: To determine fulvestrant efficacy and tolerability in Turkish patients with hormone receptor-positive metastatic breast cancer.Methods: Patients who developed metastasis while taking tamoxifen or aromatase inhibitors in the adjuvantperiod or metastatic disease at the diagnosis. Fulvestrant 500 mg was administered intramuscularly every 28days. Progression-free survival (PFS) and overall survival (OS) durations were calculated.Results: In this particular research, totally 137 patients were participated. Median PFS was 9 months (95%CI, 5.7-10.3). The 12-month PFS rate was calculated as 42%, and the 36-month PFS rate was 17%. The medianPFS was not reached in the first line use of fulvestrant in the metastatic period but 9 months and 7 months inthe second and subsequent lines respectively. Results indicated that this difference was statistically significant(p = 0.002). It was shown that patients with liver and brain metastasis had lower PFS compared patients withno liver and no brain metastasis. The estimated median OS was 38 months after fulvestrant started. The 12-month OS rate was calculated as 82.4%, and the 36-month OS rate was 50%.Conclusions: Fulvestrant contributes both PFS and OS in patients with hormone receptor-positive metastaticbreast cancer and this effect is more clear in using fulvestrant as first-line treatment.
Non-Urothelial Bladder Cancers: Single Center Experience
(2019) Yasar, Nurgul; Arıcı, Serdar; Seçmeler, Şaban; Sakin, Abdullah; Demirel, Cumhur; Can, Orcun; Geredeli, Cağlayan
Objective: Bladder cancers are classified into two groups as urothelial and non-urothelial cancer (NUBC). In this study, we investigated the clinicopathological featuresand treatment responses in patients with NUBC who were diagnosed and treated in our center.Methods: The patients who were diagnosed and treated in our hospital between 2006 and 2017 were included in the study retrospectively. Patients with urothelial ormixed bladder cancers were excluded from the study.Results: A total of 16 patients with NUBC were included in the study. Six patients had squamous cell carcinoma, six patients had small cell carcinoma and four patientshad adenocarcinoma. Thirteen patients (81%) were male and three were female. Although there was no statistically significant difference between the groups in terms oflocalization of metastases (p=0.663), the most common site of metastasis was pelvic structures in squamous cell carcinoma group and multiple distant organ metastasiswere observed in small cell carcinoma group. The median survival in squamous cell carcinoma, adenocarcinoma, and small cell carcinoma was 11±5.3, 12±10, and2±1.8 months, respectively (logrank p=0.329).Conclusion: There are no large prospective randomized clinical studies to guide treatment in NUBC. In the light of these results, we recommend that these patientsshould participate in prospective clinical studies.